315 related articles for article (PubMed ID: 23811987)
1. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.
Arima H; Oiso Y; Juul KV; Nørgaard JP
Endocr J; 2013; 60(9):1085-94. PubMed ID: 23811987
[TBL] [Abstract][Full Text] [Related]
2. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
[TBL] [Abstract][Full Text] [Related]
3. Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: a retrospective study of switching from intranasal desmopressin.
Murakami T; Hatoko T; Nambu T; Matsuda Y; Matsuo K; Yonemitsu S; Muro S; Oki S
Endocr J; 2014; 61(8):773-9. PubMed ID: 24849384
[TBL] [Abstract][Full Text] [Related]
4. Comments on "Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study"--efficacy and safety of orally disintegrating desmopressin tablets in patients with central diabetes insipidus.
Kamoi K
Endocr J; 2013; 60(9):1115. PubMed ID: 23863202
[No Abstract] [Full Text] [Related]
5. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.
Yamaguchi O; Nishizawa O; Juul KV; Nørgaard JP
BJU Int; 2013 Mar; 111(3):474-84. PubMed ID: 23046147
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
Sand PK; Dmochowski RR; Reddy J; van der Meulen EA
J Urol; 2013 Sep; 190(3):958-64. PubMed ID: 23454404
[TBL] [Abstract][Full Text] [Related]
7. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus.
Juul KV; Bichet DG; Nørgaard JP
Endocrine; 2011 Aug; 40(1):67-74. PubMed ID: 21626284
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
Weiss JP; Herschorn S; Albei CD; van der Meulen EA
J Urol; 2013 Sep; 190(3):965-72. PubMed ID: 23454402
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
Yamaguchi O; Juul KV; Falahati A; Yoshimura T; Imura F; Kitamura M
Low Urin Tract Symptoms; 2020 Jan; 12(1):8-19. PubMed ID: 31397969
[TBL] [Abstract][Full Text] [Related]
11. Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency.
Hoshino Y; Inoue K; Ikeda S; Goshima Y; Tatsushima K; Fukuhara N; Okada M; Nishioka H; Yamada S; Takeuchi Y; Takeshita A
J Clin Endocrinol Metab; 2024 Feb; 109(3):e983-e996. PubMed ID: 38019190
[TBL] [Abstract][Full Text] [Related]
12. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia.
Juul KV; Malmberg A; van der Meulen E; Walle JV; Nørgaard JP
BJU Int; 2017 May; 119(5):776-784. PubMed ID: 27862898
[TBL] [Abstract][Full Text] [Related]
13. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues.
Van de Walle J; Van Herzeele C; Raes A
Drug Saf; 2010 Apr; 33(4):261-71. PubMed ID: 20297859
[TBL] [Abstract][Full Text] [Related]
14. Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.
Almutlaq N; Eugster EA
J Pediatr; 2021 Dec; 239():228-230. PubMed ID: 34487771
[TBL] [Abstract][Full Text] [Related]
15. Management of central diabetes insipidus with oral desmopressin lyophilisate in infants.
Korkmaz HA; Demir K; Kılıç FK; Terek D; Arslanoğlu S; Dizdarer C; Ozkan B
J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):923-7. PubMed ID: 24854529
[TBL] [Abstract][Full Text] [Related]
16. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients.
Juul KV; Schroeder M; Rittig S; Nørgaard JP
J Clin Endocrinol Metab; 2014 Jun; 99(6):2181-7. PubMed ID: 24527719
[TBL] [Abstract][Full Text] [Related]
17. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
Smego AR; Backeljauw P; Gutmark-Little I
J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
[TBL] [Abstract][Full Text] [Related]
18. Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: experience of five-year treatment.
Fukuda I; Hizuka N; Takano K
Endocr J; 2003 Aug; 50(4):437-43. PubMed ID: 14599118
[TBL] [Abstract][Full Text] [Related]
19. Desmopressin 30 years in clinical use: a safety review.
Vande Walle J; Stockner M; Raes A; Nørgaard JP
Curr Drug Saf; 2007 Sep; 2(3):232-8. PubMed ID: 18690973
[TBL] [Abstract][Full Text] [Related]
20. Clinical review: Treatment of neurohypophyseal diabetes insipidus.
Oiso Y; Robertson GL; Nørgaard JP; Juul KV
J Clin Endocrinol Metab; 2013 Oct; 98(10):3958-67. PubMed ID: 23884783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
